Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma

References

• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Ansell S M, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005; 80: 1087–1097
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Nathwani B N, Harris N L, Weisenburger D D. Follicular Lymphoma. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, Lyon 2001; 162–167
   Google Scholar
• Hicks R J, Mac Manus M P, Seymour J F. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35: 165–175
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35: 186–196
   PubMed Web of Science ®Google Scholar
• Juweid M E, Wiseman G A, Vose J M, Ritchie J M, Menda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661
   PubMed Web of Science ®Google Scholar
• Schot B W, Pruim J, van Imhoff G W, Sluiter W J, Vaalburg W, Vellenga E. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 2006; 91: 490–495
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A, Brice P, Rain J D, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376–1381
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G, Hutchings M, Fields P A, O'Doherty M J, Timothy A R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514–1523
   PubMed Web of Science ®Google Scholar
• Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau J L, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 2006; 85: 759–767
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356–1363
   PubMed Web of Science ®Google Scholar
• Wohrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17: 780–784
   PubMed Web of Science ®Google Scholar
• Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006; 107: 175–183
   PubMed Web of Science ®Google Scholar
• Armitage J O. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005; 55: 368–376
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez A J, Cheson B D, Horning S J, Peterson B A, Carter W D, Varns C L, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol 2000; 11: 399–408
   PubMed Web of Science ®Google Scholar
• Delbeke D CR, Guiberteau M J, Brown M L, Royal H D, Seigel B A, Townsend D W, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. Society of Nuclear Medicine Procedure Guidelines. Reston, USA 2006
   Google Scholar
• Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A A, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773–1782
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging 2006; 33: 22–26
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Cohade C, Nakamoto Y, Fishman E K, Wahl R L. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005; 237: 1038–1045
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Leonard J P, Kuji I, Coleman M, Vallabhajosula S, Goldsmith S J. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94: 879–888
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte M F, Rigo P, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825–830
   PubMed Web of Science ®Google Scholar
• Aurora V, Winter J N. Follicular lymphoma: today's treatments and tomorrow's targets. Expert Opin Pharmacother 2006; 7: 1273–1290
   PubMedGoogle Scholar
• Advani R, Rosenberg S A, Horning S J. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454–1459
   PubMed Web of Science ®Google Scholar
• Mac Manus M P, Hoppe R T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282–1290
   PubMed Web of Science ®Google Scholar
• Ganti A K, Weisenburger D D, Smith L M, Hans C P, Bociek R G, Bierman P J, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006; 17: 920–927
   PubMed Web of Science ®Google Scholar
• Mac Manus M P, Rainer Bowie C A, Hoppe R T. What is the prognosis for patients who relapse after primary radiation therapy for early-stage low-grade follicular lymphoma?. Int J Radiat Oncol Biol Phys 1998; 42: 365–371
   PubMed Web of Science ®Google Scholar
• Metter G E, Nathwani B N, Burke J S, Winberg C D, Mann R B, Barcos M, et al. Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies. J Clin Oncol 1985; 3: 25–38
   PubMed Web of Science ®Google Scholar
• Martin A R, Weisenburger D D, Chan W C, Ruby E I, Anderson J R, Vose J M, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85: 3671–3678
   PubMed Web of Science ®Google Scholar
• Glas A M, Kersten M J, Delahaye L J, Witteveen A T, Kibbelaar R E, Velds A, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301–307
   PubMed Web of Science ®Google Scholar
• Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi Y E, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 4643–4651
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Goldsmith S J, Leonard J P, Christos P, Furman R R, Atasever T, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107: 2678–2687
   PubMed Web of Science ®Google Scholar
• Buckstein R, Pennell N, Berinstein N L. What is remission in follicular lymphoma and what is its relevance?. Best Pract Res Clin Haematol 2005; 18: 27–56
   PubMed Web of Science ®Google Scholar